Aging
Conditions
Keywords
Exercise, Hypertrophy, Strength, Power
Brief summary
The goal of this clinical trial is to compare the effects of protein consumption before sleep or immediately after exercise during 12 weeks of resistance exercise training in older adults. The main questions it aims to answer are: Are there differences in muscle growth or strength during 12 weeks of resistance training when 40 grams of protein is consumed either before sleep or immediately after exercise? Are there differences in cognitive performance during 12 weeks of resistance training when 40 grams of protein is consumed either before sleep or immediately after exercise? This study is a randomized double-blind placebo-controlled study. Participants will be randomly allocated into 1 of 3 groups. All three groups will perform the same 12-week resistance exercise training program two times per week and consume 40 g of protein: 1) Immediately post-exercise, 2) 30 minutes prior to sleep, or 3) no supplemental protein (control). Test of muscle growth and strength, and cognitive performance will be measure before, during, and after the exercise training program. Researchers will compare the 3 conditions to determine if consume protein after exercise or before sleep during 12 weeks of resistance exercise training affects muscle growth and strength, and cognitive performance.
Interventions
DIETARY_SUPPLEMENTProtein
Post-exercise protein group consumed protein immediately after exercise sessions. Pre-sleep protein group consumed protein 30 minutes before sleep.
OTHERPlacebo
Resistance exercise training only group did not consume supplemental protein.
Sponsors
Florida State University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
60 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Male between 60-75 years old at the time of enrollment.
Exclusion criteria
* Diagnosis of cardiac or peripheral vascular disease * Stroke, kidney dysfunction * Metabolic disease * Uncontrolled hypertension * Orthopedic limitations * Skeletal muscle complications * Milk allergy * Psychiatric conditions * Use of psychotropic drugs * Cognitive impairment (scoring 26 points or less on the Montreal Cognitive Assessment) * Participation in a structured regular exercise program within the past 6 months * Actively attempting to increase or decrease body mass * Body mass index (BMI) of ≥ 35 kg/m2
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Muscle thickness | Week 0, 6, and 12 | Change in muscle thickness of the quadriceps muscles in centimeters from week 0 (baseline) to week 6 (midpoint) to week 12 (end of study). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sleep latency | Week 0 and 12 | Changes in actigraphy watch measured sleep latency in minutes from week 0 (baseline) to week 12 (end of study). |
| Measures associated with sleep | Week 0 and 12 | Changes in actigraphy watch measured sleep efficiency (ratio of time spent asleep to the time spent in bed) in percentage from week 0 (baseline) to week 12 (end of study). |
| Maximum muscular strength | Week 0, 6, and 12 | Changes in strength of the chest press and leg press exercises in kilograms from week 0 (baseline) to week 6 (midpoint) to week 12 (end of study). |
| Muscle power | Week 0, 6, and 12 | Changes in power (Watts) during a sit-to-stand task from week 0 (baseline) to week 6 (midpoint) to week 12 (end of study). |
| Nitrogen balance | Week 0 and 12 | Changes in urinary nitrogen balance (grams per day) from week 0 (baseline) to week 12 (end of study). |
| Measures associated appetite | Week 0, 6, and 12 | Changes in subjective measures of hunger, satiety, and desire to eat on a 0-100 millimeter (higher values indicating stronger feeling) visual analog scale from week 0 (baseline) to week 6 (midpoint) to week 12 (end of study). |
| Total sleep time | Week 0 and 12 | Changes in actigraphy watch measured total sleep time in hours from week 0 (baseline) to week 12 (end of study). |
| Free insulin-like growth factor 1 | Week 0 and 12 | Changes in plasma free insulin-like growth factor 1 concentration (nanogram per deciliter) from week 0 (baseline) to week 12 (end of study). |
| Mood | Week 0 and 12 | Changes in the Profile of Mood State rating scale categories of tension, depression, anger, fatigue, confusion, vigor, and total mood disturbance from week 0 (baseline) to week 12 (end of study) via a 1 to 5 scale (higher score indicates stronger feeling). |
| Cognitive performance | Week 0 and 12 | Changes in the number of correct responses during the digit symbol substitution task and pattern comparison tests from week 0 (baseline) to week 12 (end of study). |
Countries
United States
Outcome results
None listed